Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine
Links: https://delta.larvol.com/Products/?ProductId=2a41421b-2069-4661-ab62-7631bc4eb36d, https://synapse.patsnap.com/drug/9269a1e8dda548e9babb2434396151ed
From Ben Williams Book: A variation in the use of dendritic cells first subjected tumor tissue to a heat-shock treatment to elevate the expression of heat-shock proteins, which were extracted from the blood and incubated with dendritic cells from individual patients. In a clinical trial (163) conducted at UCSF and Columbia for patients with recurrent heavily pretreated tumors, the vaccine produced a median survival of 42.6 weeks (about 9.8 months), which compares favorably to the 6-month survival time for historical controls, and is comparable to the 9-11 months when Avastin is used with patients with recurrent tumors.
A subsequent news release from Agenus, Inc, a biotech company sponsoring the research, reported the results of phase II clinical trial in which the heat-shock dendritic vaccine was combined with the standard Stupp protocol (164). Median progression-free survival was 17.8 months and median survival was 23.8 months. This median progression-free survival of 17.8 months is perhaps the longest PFS yet seen in any substantially sized phase 2 trial for newly diagnosed glioblastoma.
Follow-up data (reference 339, abstract 2011) presented at the ASCO 2015 conference revealed that patients with high PD-L1 expression (the ligand for the PD-1 immune checkpoint on the surface of immune cells which is the target for the therapeutic antibodies nivolumab and pembrolizumab) had a median survival of 18 months, while those with low expression of PD-L1 had a median survival of 44.7 months. This finding suggests that efficacy of the heat shock protein peptide vaccine could be greatly improved by co-administration of PD-1 antibodies such as nivolumab or pembrolizumab.Property "Has original text" (as page type) with input value "A variation in the use of dendritic cells first subjected tumor tissue to a heat-shock</br>treatment to elevate the expression of heat-shock proteins, which were extracted from the</br>blood and incubated with dendritic cells from individual patients. In a clinical trial (163)</br>conducted at UCSF and Columbia for patients with recurrent heavily pretreated tumors,</br>the vaccine produced a median survival of 42.6 weeks (about 9.8 months), which</br>compares favorably to the 6-month survival time for historical controls, and is</br>comparable to the 9-11 months when Avastin is used with patients with recurrent tumors.</br></br>A subsequent news release from Agenus, Inc, a biotech company sponsoring the research,</br>reported the results of phase II clinical trial in which the heat-shock dendritic vaccine was</br>combined with the standard Stupp protocol (164). Median progression-free survival was</br>17.8 months and median survival was 23.8 months. This median progression-free</br>survival of 17.8 months is perhaps the longest PFS yet seen in any</br>substantially sized phase 2 trial for newly diagnosed glioblastoma.</br></br>Follow-up data (reference 339, abstract 2011) presented at the ASCO 2015 conference</br>revealed that patients with high PD-L1 expression (the ligand for the PD-1 immune</br>checkpoint on the surface of immune cells which is the target for the therapeutic</br>antibodies nivolumab and pembrolizumab) had a median survival of 18 months, while</br>those with low expression of PD-L1 had a median survival of 44.7 months. This finding</br>suggests that efficacy of the heat shock protein peptide vaccine could be greatly improved</br>by co-administration of PD-1 antibodies such as nivolumab or pembrolizumab." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
